Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
概览
- 阶段
- 2 期
- 干预措施
- Azacitidine and Venetoclax
- 疾病 / 适应症
- Acute Myeloid Leukemia
- 发起方
- University of Colorado, Denver
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Duration of response to azacitidine and venetoclax treatment
- 状态
- 已完成
- 最后更新
- 23天前
概览
简要总结
This study is being done to determine if treatment with azacitidine and venetoclax is effective treatment for elderly patients with acute myeloid leukemia (AML) who have not received previous treatment. Azacitidine and venetoclax will be given as induction treatment followed by venetoclax maintenance treatment for patients who respond to the induction treatment.
详细描述
This is a phase 2 study for elderly patients who have not received previous treatment for acute myeloid leukemia (AML). Up to 42 patients will be enrolled. All patients will be treated with azacitidine and venetoclax until a minimal residual disease (MRD) negative response is achieved. Once patients achieve a MRD negative composite response, azacitidine will be discontinued and venetoclax dose will be decreased to "maintenance" dose.
研究者
入排标准
入选标准
- •Subject must have confirmation of non-APL AML by WHO criteria and be ineligible or unwilling to undergo treatment with a standard cytarabine and anthracycline induction regimen due to co-morbidities or other factors
- •Subject must have received no prior treatment for AML; hydroxyurea is not considered a treatment and is allowed
- •Subject must be ≥ 60 years of age
- •Subject must have a projected life expectancy of at least 12 weeks
- •Subject must have an Eastern Cooperative Oncology Group (ECOG) Performance status of ≤2
- •Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula
- •Subject must have adequate liver function as demonstrated by:
- •aspartate aminotransferase (AST) ≤ 3.0 × ULN\*
- •alanine aminotransferase (ALT) ≤ 3.0 × ULN\*
- •bilirubin ≤ 3.0 × ULN, unless due to Gilbert's syndrome\*
排除标准
- •Subject has received treatment with a hypomethylating agent and/or other chemotherapeutic agent either conventional or experimental for myelodysplastic syndrome (MDS) or AML
- •Subject has acute promyelocytic leukemia
- •Subject has known active CNS involvement from AML
- •Subject is known to be positive for HIV. HIV testing is not required
- •Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV (i.e., HBs Ag, anti-HBs+ and anti-HBc-) may participate
- •Subject has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 5 half-lives prior to first dose of study drug
- •Subject has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within 30 days prior to first dose of study drug
- •Subject has received the following within 7 days prior to the first dose of the study drug:
- •Steroid therapy for anti-neoplastic intent;
- •Strong and Moderate CYP3A inhibitors (see Appendix A for examples)
研究组 & 干预措施
Azacitidine and Venetoclax
On day 1 of cycle 1, Azacitidine 75 mg/m2 will be given by injection or infusion, and will continue for 7 days. Azacitidine doses will be given in subsequent cycles for patients who do not achieve response. Venetoclax will be administered orally once daily on days 2 through 28 in cycle 1. Beginning with cycle 2, and each subsequent cycle, venetoclax will be administered Days 1 through 28.
干预措施: Azacitidine and Venetoclax
结局指标
主要结局
Duration of response to azacitidine and venetoclax treatment
时间窗: From the first day a response is documented to the first day of disease progression
Determine how long responses last in patients treated with azacitidine and venetoclax followed by venetoclax maintenance treatment
Duration of Remission Response to Azacitidine and Venetoclax Treatment + Maintenance Therapy
时间窗: From the first day a response is documented to the first day of disease progression
To determine the remission duration experienced by elderly previously untreated AML patients with azacitidine plus venetoclax followed by venetoclax alone as a maintenance therapy for patients who achieve a minimal residual disease (MRD) negative remission
次要结局
- Frequency of Minimal Residual Disease (MRD) negative composite responses within the "induction phase" of azacitidine and venetoclax(From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years)
- The time needed to achieve an MRD negative composite response(From first dose of treatment to first day response is documented by bone marrow biopsy)
- The one-year overall survival (OS) of older, newly diagnosed AML patients treated with "induction phase" of azacitidine with venetoclax followed by a maintenance Phase of venetoclax alone.(From date of study enrollment to one year after enrollment)
- Hematologic Toxicity as defined by the 2017 ELN AML Recommendations(From the day venetoclax with azacitidine is administered to the end of maintenance venetoclax alone, up to one year)
- Response Rate, With Responses Defined as Complete Remission (CR), Complete Remission With Incomplete Blood Count Recovery (CRi) and Morphologic Leukemia Free State (MLFS).(From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years)
- MRD-Negativity Incidence(From Day 28, the first day a response is documented to end of cycle bone marrow biopsies, through 5 years)
- To Determine the Median Time to Achieve a MRD Negative Composite Response(From first dose of treatment to first day response is documented by bone marrow biopsy, on average 30 days)